ARQT
NASDAQArcutis Biotherapeutics Inc.
Price$21.55-2.41 (-10.08%)
2026-03-052026-06-08
News · 26 weeks76-86%
2025-12-142026-06-07
Mix3290d
- Other14(44%)
- Insider8(25%)
- SEC Filings7(22%)
- Earnings2(6%)
- Leadership1(3%)
Latest news
25 items- PRArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 44,000 restricted stock units of Arcutis' common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of June 1, 2026, as a material inducement to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted st
- PRNew Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical DermatologyExpert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populationsThis is the second published manuscript from the Genital Psoriasis Wellness Consortium, a multidisciplinary group of expert cliniciansGenital involvement occurs in approximately two-thirds of the nine million individuals with plaque psoriasis in the United States WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the publication of a new manuscript in the Ameri
- PRArcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare ConferenceWESTLAKE VILLAGE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the Goldman Sachs 47th Annual Global Healthcare Conference, taking place June 8-10, 2026, in Miami. Details for the Company's participation are as follows: Fireside Chat: Tuesday, June 9, 2026, at 2:00 p.m. ET The webcast for this conference may be accessed via the "Events" section of the Company's website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference. Ab
- INSIDERSVP Chief Financial Officer Vairavan Latha sold $9,157 worth of shares (435 units at $21.05), decreasing direct ownership by 0.50% to 85,978 units (SEC Form 4) to cover withholding tax4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDEROfficer Burnett Patrick sold $4,673 worth of shares (222 units at $21.05), decreasing direct ownership by 0.18% to 120,244 units (SEC Form 4) (tax liability)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Arcutis Biotherapeutics Inc.SCHEDULE 13G - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- SECSEC Form 144 filed by Arcutis Biotherapeutics Inc.144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- PRArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WESTLAKE VILLAGE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 269,000 restricted stock units of Arcutis' common stock as well as options to purchase an aggregate of 70,000 shares of Arcutis' common stock to 40 newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of May 1, 2026, as an inducement material to the new employees entering into employmen
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- INSIDEROfficer Matsuda Masaru sold $192,415 worth of shares (8,256 units at $23.31) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 126,689 units (SEC Form 4) to cover taxes4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDEROfficer Burnett Patrick sold $16,150 worth of shares (684 units at $23.61), decreasing direct ownership by 0.56% to 120,466 units (SEC Form 4) (withholding tax)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERSVP Chief Financial Officer Vairavan Latha sold $31,662 worth of shares (1,341 units at $23.61), decreasing direct ownership by 2% to 86,413 units (SEC Form 4) (tax liability)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDEROfficer Watanabe Todd sold $74,893 worth of shares (3,172 units at $23.61), decreasing direct ownership by 0.44% to 720,755 units (SEC Form 4) (for withholding tax)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- SECSEC Form 10-Q filed by Arcutis Biotherapeutics Inc.10-Q - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)
- SECArcutis Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)
- PRArcutis Announces First Quarter 2026 Financial Results and Provides Business UpdateQ1 2026 net product revenue for ZORYVE® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025Continued strong demand for ZORYVE despite typical Q1 seasonality, with continued growth in share of branded non-steroidal topical treatmentsSubmitted supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% to the U.S. Food and Drug Administration (FDA) to expand the indication for the treatment of atopic dermatitis in infants ages 3 to 24 monthsCompleted enrollment in ZORYVE foam 0.3% Maximum Usage Systemic Exposure (MUSE) trial in children with plaque psoriasis of the scalp and body ages 2 to 11 yearsInitiated Phase 1a/1b, first-in-huma
- INSIDERDirector Welgus Howard G. sold $164,220 worth of shares (7,144 units at $22.99) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 32,600 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- SECSEC Form 144 filed by Arcutis Biotherapeutics Inc.144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- PRArcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 MonthsSubmission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitisOnce-daily ZORYVE cream was well tolerated with a safety profile consistent with that in older children and adultsAtopic dermatitis impacts 1 million children under the age of 2 in the United StatesOnly one other FDA-approved topical non-steroidal anti-inflammatory agent available for this vulnerable population WESTLAKE VILLAGE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, t
- PRArcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis GuidelinesStrong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic dermatitis affects approximately 9.6 million children in the United States WESTLAKE VILLAGE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream has received a strong recommendation, with high certainty of clinical evidence, in the American Academy of Dermatology (AAD) clinical practice gu
- SECSEC Form S-8 filed by Arcutis Biotherapeutics Inc.S-8 - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)
- SECSEC Form DEFA14A filed by Arcutis Biotherapeutics Inc.DEFA14A - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)
- SECSEC Form DEF 14A filed by Arcutis Biotherapeutics Inc.DEF 14A - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)
- PRArcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its first quarter 2026 financial results and provide a business update on Wednesday, May 6, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30pm ET. A live webcast of the call and related presentation materials will be available on the "Events" section of the Company's website. A replay of the webcast will be available on the Arcutis investor website following the conferen
ARQT FAQ
7 questionsWhat does Arcutis Biotherapeutics Inc. do?
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252...Where does ARQT stock trade?
Arcutis Biotherapeutics Inc. (ARQT) is listed on NASDAQ.What sector and industry is ARQT in?
Arcutis Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Arcutis Biotherapeutics Inc. go public?
Arcutis Biotherapeutics Inc. (ARQT) completed its IPO in 2020.What are analysts saying about ARQT?
Arcutis Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Neutral with a $1800.00 price target on 2025-07-25.What companies are similar to ARQT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ARQT side-by-side with any of them on Quantisnow.How can I track ARQT on Quantisnow?
Quantisnow aggregates Arcutis Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARQT to receive live email and push alerts on every new disclosure.